b'REALIZING FUTURESTargeted Immunotherapy Allows theElimination of Toxic Chemoradiotherapyin Adolescents and Young Adults withHodgkin Lymphoma Ryan Danyluk was 16 years of age when he was diagnosed with Hodgkin Lymphoma and became a patient of Dr. Cairo. He benefitted fromDr. Cairos investigational treatment, undergoing six months of targeted immunotherapy. Today, this healthy 21-year-old is a recipient of our Survivor Scholarship, microgrants we award to help childhood cancer survivors achieve their college ambitions. After graduating with a civil engineering degree from Wentworth Institute of Technology, Ryan is now pursuing his lifelong dream of being a civil engineer, just like his dad. Ryan is flourishing today because of advances in cancer treatment, partially made possible by PCRF. Ryans experience illustrates the results that can be achieved by investing in research. In the 40 years since I have been involved with PCRF, treatment for this type of cancer has changed dramaticallyweve eliminated radiation, introduced immunotherapy and reduced both chemotherapy and the total length of treatment, all while increasing survival rates from 60% in 1982 to greater than 95% in 2022. Stories like Ryans are why I got involved in medicine. My greatest thrill is curing a patient of an otherwise lethal disease. Equally satisfying is seeing my patients and families years after their diagnosis and treatment enjoying their lives, successful in their professional careers and raising a new family of their own. I am humbled bythe fact that the success of my research, in large part supported by grants from PCRF, has saved the lives of thousands of children and is being translated over the globe.Mitchell Cairo, MDNew York Medical CollegeMarie Fareri Childrens Hospital13'